MA43250B1 - Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues - Google Patents
Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux droguesInfo
- Publication number
- MA43250B1 MA43250B1 MA43250A MA43250A MA43250B1 MA 43250 B1 MA43250 B1 MA 43250B1 MA 43250 A MA43250 A MA 43250A MA 43250 A MA43250 A MA 43250A MA 43250 B1 MA43250 B1 MA 43250B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- treatment
- drug abuse
- dependence
- oxadiazaspiro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Addiction (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La présente invention concerne des composés ayant une activité pharmacologique dirigée contre le récepteur sigma (s), et plus particulièrement des composés oxadiazaspiro ayant cette activité pharmacologique, des procédés de préparation de ces composés, des compositions pharmaceutiques les comprenant, ainsi que leur utilisation thérapeutique, en particulier pour le traitement de l'abus de drogues et de la toxicomanie.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15382566 | 2015-11-16 | ||
PCT/EP2016/001907 WO2017084752A1 (fr) | 2015-11-16 | 2016-11-15 | Composés oxadiazaspiro pour le traitement de l'abus de drogues et de la toxicomanie |
Publications (2)
Publication Number | Publication Date |
---|---|
MA43250A MA43250A (fr) | 2021-04-14 |
MA43250B1 true MA43250B1 (fr) | 2022-12-30 |
Family
ID=54707728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA43250A MA43250B1 (fr) | 2015-11-16 | 2016-11-15 | Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues |
Country Status (29)
Country | Link |
---|---|
US (2) | US10927128B2 (fr) |
EP (1) | EP3377500B1 (fr) |
JP (1) | JP6884974B2 (fr) |
KR (1) | KR20180080327A (fr) |
CN (1) | CN108349999A (fr) |
AR (1) | AR106697A1 (fr) |
AU (1) | AU2016356488B2 (fr) |
CA (1) | CA3002286A1 (fr) |
CO (1) | CO2018004665A2 (fr) |
DK (1) | DK3377500T3 (fr) |
ES (1) | ES2932000T3 (fr) |
HR (1) | HRP20221343T1 (fr) |
HU (1) | HUE060275T2 (fr) |
IL (1) | IL259035B (fr) |
LT (1) | LT3377500T (fr) |
MA (1) | MA43250B1 (fr) |
MX (1) | MX2018005439A (fr) |
MY (1) | MY193423A (fr) |
PH (1) | PH12018500814A1 (fr) |
PL (1) | PL3377500T3 (fr) |
PT (1) | PT3377500T (fr) |
RS (1) | RS63734B1 (fr) |
SG (1) | SG11201803153RA (fr) |
SI (1) | SI3377500T1 (fr) |
TN (1) | TN2018000122A1 (fr) |
TW (1) | TWI756196B (fr) |
UA (1) | UA123775C2 (fr) |
WO (1) | WO2017084752A1 (fr) |
ZA (1) | ZA201802845B (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018005439A (es) | 2015-11-16 | 2018-11-09 | Esteve Labor Dr | Compuestos oxadiazoespiricos para el tratamiento del abuso y la adiccion a las drogas. |
WO2020157026A1 (fr) * | 2019-01-28 | 2020-08-06 | Esteve Pharmaceuticals, S.A. | Dérivés hydroxylés de composés de 1-oxa-4,9-diazaspiro-undécane ayant une activité multimodale contre la douleur |
CA3230908A1 (fr) | 2021-09-20 | 2023-03-23 | Jose-Miguel Vela-Hernandez | Composes oxadiazaspiro destines a etre utilises dans le traitement de la degenerescence des motoneurones ou dans la neuroprotection |
WO2024105225A1 (fr) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Combinaisons synergiques d'un antagoniste du récepteur sigma 1 (s1r) et d'un inhibiteur d'époxyde hydrolase soluble (sehi) et leur utilisation dans le traitement de la douleur |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4244961A (en) * | 1978-10-26 | 1981-01-13 | Syntex (U.S.A.) Inc. | 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents |
US4332804A (en) | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353900A (en) | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
US4353901A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US6114541A (en) | 1997-03-10 | 2000-09-05 | Hoffmann-La Roche Inc. | Method for the preparation of α-Bromo-Lactam derivatives |
KR100863854B1 (ko) * | 2004-02-10 | 2008-10-15 | 에프. 호프만-라 로슈 아게 | 케모카인 ccr5 수용체 조절제 |
ATE495730T1 (de) | 2004-03-03 | 2011-02-15 | Vital Health Sciences Pty Ltd | Alkaloid-formulierungen |
EP1634873A1 (fr) | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Inhibiteurs des récepteurs sigma |
JP5135795B2 (ja) * | 2004-08-27 | 2013-02-06 | 小野薬品工業株式会社 | 塩基性基を含有する化合物およびその用途 |
CN101228127B (zh) | 2005-05-30 | 2012-05-16 | Msdk.K.公司 | 哌啶衍生物 |
CN101203567A (zh) * | 2005-06-07 | 2008-06-18 | 西巴特殊化学品控股有限公司 | 抗刮擦聚烯烃 |
DE102005030051A1 (de) | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
KR101347102B1 (ko) | 2005-10-19 | 2014-01-03 | 그뤼넨탈 게엠베하 | 신규한 바닐로이드 수용체 리간드 및 약제를 제조하기 위한이의 용도 |
PT1961744E (pt) | 2005-11-18 | 2013-05-15 | Ono Pharmaceutical Co | Composto que contém um grupo básico e sua utilização |
EP1829869A1 (fr) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Dérivés de 4,5,6,7-tétrahydrobenzo[b]thiophène et leur utilisaton comme ligands du récepteur sigma |
EP1847542A1 (fr) | 2006-04-21 | 2007-10-24 | Laboratorios del Dr. Esteve S.A. | Dérivés de spiro[benzopyran] ou de spiro[benzofuran] comme antagonistes du récepteur sigma |
CN101622241B (zh) | 2007-03-01 | 2013-05-22 | 田边三菱制药株式会社 | 苯并咪唑化合物及其医药用途 |
EP1982714A1 (fr) | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Pyrano-pyrazole-aminés |
EP2020414A1 (fr) * | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | Derivés spiro[piperidine-4,4'-thieno[3,2-c]pyran] et composés similaires en tant que inhibiteurs du recepteur sigma pour le traitement de pyschose |
US20110190280A1 (en) | 2007-08-29 | 2011-08-04 | George Adjabeng | Thiazole And Oxazole Kinase Inhibitors |
EP2070933A1 (fr) | 2007-12-07 | 2009-06-17 | Laboratorios del Dr. Esteve S.A. | Composants triazoliques tricycliques |
ES2394547T3 (es) | 2008-02-06 | 2013-02-01 | Astrazeneca Ab | Compuestos |
EP2108643A1 (fr) * | 2008-04-10 | 2009-10-14 | Laboratorios Del. Dr. Esteve, S.A. | 4-Méthyl-4, 5-dihydro-1H-pyrazole-3-carboxamide utile en tant qu'antagoniste neutre de cannabinoïde CB1 |
GB201016912D0 (en) * | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
WO2012125613A1 (fr) | 2011-03-14 | 2012-09-20 | Vertex Pharmaceuticals Incorporated | Amides de pipéridine spirocycliques morpholines utilisés en tant que modulateurs de canaux ioniques |
GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
WO2013052716A1 (fr) * | 2011-10-07 | 2013-04-11 | Glaxosmithkline Llc | Inhibiteurs de l'acide gras synthase |
JPWO2013115294A1 (ja) * | 2012-01-31 | 2015-05-11 | 東レ株式会社 | ジアザスピロウレア誘導体及びその医薬用途 |
WO2015017305A1 (fr) | 2013-07-31 | 2015-02-05 | Merck Sharp & Dohme Corp | Inhibiteurs du canal potassique médullaire externe rénal |
TW201615643A (zh) * | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性之1-氧雜-4,9-二氮雜螺十一烷化合物之烷基與芳基衍生物 |
TWI685497B (zh) * | 2014-06-02 | 2020-02-21 | 西班牙商伊史帝夫製藥公司 | 具有多重模式抗疼痛活性的1-氧雜-4,9-二氮雜螺十一烷化合物之烷基衍生物 |
TW201615642A (zh) | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性的1-氧雜-4,9-二氮雜螺十一烷化合物之醯胺衍生物 |
US10513518B2 (en) * | 2015-01-29 | 2019-12-24 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
MX2018005439A (es) | 2015-11-16 | 2018-11-09 | Esteve Labor Dr | Compuestos oxadiazoespiricos para el tratamiento del abuso y la adiccion a las drogas. |
-
2016
- 2016-11-15 MX MX2018005439A patent/MX2018005439A/es unknown
- 2016-11-15 SG SG11201803153RA patent/SG11201803153RA/en unknown
- 2016-11-15 ES ES16797458T patent/ES2932000T3/es active Active
- 2016-11-15 PT PT167974583T patent/PT3377500T/pt unknown
- 2016-11-15 HU HUE16797458A patent/HUE060275T2/hu unknown
- 2016-11-15 JP JP2018524257A patent/JP6884974B2/ja active Active
- 2016-11-15 SI SI201631621T patent/SI3377500T1/sl unknown
- 2016-11-15 CA CA3002286A patent/CA3002286A1/fr active Pending
- 2016-11-15 LT LTEPPCT/EP2016/001907T patent/LT3377500T/lt unknown
- 2016-11-15 DK DK16797458.3T patent/DK3377500T3/da active
- 2016-11-15 KR KR1020187017092A patent/KR20180080327A/ko not_active Application Discontinuation
- 2016-11-15 WO PCT/EP2016/001907 patent/WO2017084752A1/fr active Application Filing
- 2016-11-15 PL PL16797458.3T patent/PL3377500T3/pl unknown
- 2016-11-15 MY MYPI2018701503A patent/MY193423A/en unknown
- 2016-11-15 UA UAA201806353A patent/UA123775C2/uk unknown
- 2016-11-15 RS RS20221052A patent/RS63734B1/sr unknown
- 2016-11-15 EP EP16797458.3A patent/EP3377500B1/fr active Active
- 2016-11-15 AR ARP160103486A patent/AR106697A1/es unknown
- 2016-11-15 TN TNP/2018/000122A patent/TN2018000122A1/en unknown
- 2016-11-15 MA MA43250A patent/MA43250B1/fr unknown
- 2016-11-15 TW TW105137236A patent/TWI756196B/zh active
- 2016-11-15 US US15/774,407 patent/US10927128B2/en active Active
- 2016-11-15 AU AU2016356488A patent/AU2016356488B2/en active Active
- 2016-11-15 CN CN201680066748.9A patent/CN108349999A/zh active Pending
- 2016-11-15 HR HRP20221343TT patent/HRP20221343T1/hr unknown
-
2018
- 2018-04-16 PH PH12018500814A patent/PH12018500814A1/en unknown
- 2018-04-30 IL IL259035A patent/IL259035B/en active IP Right Grant
- 2018-04-30 CO CONC2018/0004665A patent/CO2018004665A2/es unknown
- 2018-04-30 ZA ZA2018/02845A patent/ZA201802845B/en unknown
-
2020
- 2020-12-21 US US17/128,738 patent/US11649248B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39145B1 (fr) | Dérivés de pipérazine ayant une activité multimode contre la douleur | |
MA41179A (fr) | Composés inhibiteurs de parg | |
PH12015502658A1 (en) | 3,4-dihydroisoquinolin-2 (1h)-yl compounds | |
MA39898B1 (fr) | Composés 4-amino-imidazoquinoline | |
MX2022016427A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
MA43250B1 (fr) | Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues | |
MA38284B1 (fr) | Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one | |
MA47356B1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
WO2018067520A3 (fr) | Procédés et agents thérapeutiques | |
MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
NZ744982A (en) | Therapeutic compounds | |
ZA202001295B (en) | Thiazolopyridine derivatives as adenosine receptor antagonists | |
MX2016006603A (es) | Compuestos piperidinicos con actividad multimodal contra el dolor. | |
MX2017006513A (es) | Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor. | |
ZA202001780B (en) | Bezimidazole derivatives as adenosine receptor antagonists | |
MA43158B1 (fr) | Composés oxa-diazadispiro possédant une activité contre la douleur | |
MX2018003564A (es) | 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer. | |
MA39101A1 (fr) | Agonistes a1 de l'adénosine utilisés comme médicaments contre les maladies des reins | |
MA38636A1 (fr) | Composés de 3,4-dihydroisoquinoléin-2(1h)-yle | |
MX2024005997A (es) | Antagonistas del receptor de adenosina. | |
MX2018004776A (es) | Compuestos oxaazaespiricos con actividad contral el dolor. | |
MA35894B1 (fr) | Composés d'oxazolidine-2-one et utilisations de ceux-ci en tant qu'inhibiteurs des pi3k | |
MX2018002786A (es) | Composicion farmaceutica de vinpocetina. | |
MA39446A1 (fr) | Compositions pharmaceutiques pour traiter des maladies infecteuses | |
JO3621B1 (ar) | مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll |